Delecion infrecuente en el codon 67 del gen de la transcriptasa reversa de hiv en falla al tratamiento antirretroviral

Medicina

Volumn 61, Issue 2, 2001, Pages 193-195

  Giri, Juan ^a   Rueda, Horacio Jauregui ^b   Monticelli, Alejandra ^b   Pirola, Daniel A ^a   Planes, Norma ^a,c  

^a Centro Diagnostico de Virus   (Argentina)

^b Fund A/I/VIH SIDA(FAIVIH/S)   (Argentina)

^c NONE   (Argentina)

Author keywords

Genotyping; HIV; Resistance; Salvage therapy

Indexed keywords

ANTI HUMAN IMMUNODEFICIENCY VIRUS AGENT; PROTEINASE; RNA DIRECTED DNA POLYMERASE; ZIDOVUDINE;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; ADULT; AMINO ACID SEQUENCE; ANTIBIOTIC RESISTANCE; ARTICLE; CASE REPORT; FEMALE; GENE DELETION; GENETICS; GENOTYPE; HUMAN; NUCLEOTIDE SEQUENCE; TREATMENT FAILURE;

ACQUIRED IMMUNODEFICIENCY SYNDROME; ADULT; AMINO ACID SEQUENCE; ANTI-HIV AGENTS; BASE SEQUENCE; DRUG RESISTANCE, MICROBIAL; FEMALE; GENE DELETION; GENOTYPE; HIV PROTEASE; HUMANS; RNA-DIRECTED DNA POLYMERASE; TREATMENT FAILURE; ZIDOVUDINE;

EID: 17544393377     PISSN: 00257680     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (11)

1. Suárez C, Jahnke N, Montaner JCG. El estado actual del tratamiento de la infección por HIV. Medicina (Buenos Aires) 1999; 59: 385-92.
2. Rodriguez Fosado R, Briones C, Soriano V. Introduction of HIV drug resistance testing in clinical practice. AIDS 1999; 13: 1007-14.
3. Lorenzi P, Cpravil M, the Swiss HIV Cohort Study et al. Impact of drug resistance mutations on virologic response to salvage therapy. .AIDS 1999; 13: F17-F21.
4. Durant J, Clevenbergh P, Halfon P, et al. Drug-resistance genotyping in HIV-1 therapy: the VIRADAPT randomised controlled trial. Lancet 1999; 353: 2195-9.
5. Baxter JD, Mayers DL, Wentworth DN, et al. A randomized study of antiretroviral management based on plasma genotypic antiretroviral resistance testing in patients failing therapy. CPCRA 046 Study Team for the Terry Beirn Community Programs for Clinical Research on AIDS. AIDS 2000; 14: F83-93.
6. Vandamme AM, Van Laethem K, De Clercq E. Managing resistance to anti-HIV drugs. Drugs 1999; 57: 337-61.
7. Cabana M, C otet B, Martinez MA. Emergence and genetic evolution of HIV-1 variants with mutations conferring resistance to multiple reverse transcriptase and protease inhibitors. J Med Virol 1999; 59: 480-90.
8. Imamichi T, Sinha T, Imamichi H, et al. High-level resistance to 3′-azido-3′deoxythimidine due to a deletion in the reverse transcriptase gene of Human Immunodeficiency Virus Type 1. J Virol 2000; 74: 1023-8
9. De Jong JJ, Goudsmit J, Lukashov VV, et al. Insertion of two amino acids combined with changes in reverse transcriptase containing tyrosine-215 of HIV-1 resistant to multiple nucleoside analogs. AIDS 1999; 13: 75-80.
10. Kim EY, Vrang L, Oberg B, et al. Anti-HIV-1 activity of 3′-fluoro-3′-deoxythymidine for different multidrug-resistant mutants. VII Conference on Retroviruses and Opportunistic Infections, San Francisco, California, USA, February 2000. Abstr. 742.
11. Winters MA, Cooley KL, Girard YA, et al. A 6-Basepair insert in the reverse transcriptase gene of Human Immunodeficiency Virus Type 1 confers resistance to multiple nucleoside inhibitors. J Clin Invest 1998; 102: 1769-75.